| Raylumis (tanezumab) / Eli Lilly, Pfizer |
NCT04163419: Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis |
|
|
| Active, not recruiting | 2 | 9 | US | Tanezumab, PF-04383119, Placebo | Massachusetts General Hospital, Pfizer | Schwannomatosis, Pain | 09/22 | 09/24 | | |
| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron |
2018-001411-71: A study to look at fluid from knee and hip joints in studies with fasinumab for treatment of adults with pain from osteoarthritis of the knee or hip |
|
|
| Not yet recruiting | 2 | 200 | Europe | Fasinumab, Naproxen, REGN475, Solution for injection in pre-filled syringe, Capsule, Diclofenac, Naproxen, Celecoxib | Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. | Pain due to osteoarthritis of the knee, Pain of the knee due to a joint disease that results from breakdown of joint cartilage and underlying bone, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
2018-001618-13: A study to look at samples from knee and hip replacements in studies with fasinumab for treatment of adults with pain from osteoarthritis of the knee or hip |
|
|
| Not yet recruiting | 2 | 50 | Europe | Fasinumab, Naproxen, REGN475, Solution for injection in pre-filled syringe, Capsule, Diclofenac, Naproxen, Celecoxib | Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. | Pain due to osteoarthritis of the knee or hip, Pain of the knee or hip due to a joint disease that results from breakdown of joint cartilage and underlying bone, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
2017-004921-33: A study to evaluate the effect of fasinumab compared to placebo on peripheral nerves in patients with pain due to OA of the hip or knee. |
|
|
| Not yet recruiting | 2 | 180 | Europe | Fasinumab, REGN475, Solution for injection in pre-filled syringe | Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. | Pain due to osteoarthritis of the hip or knee, Pain of the knee or hip due to a joint disease that results from breakdown of joint cartilage and underlying bone, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
| Engedi 1000 / Ensol Biosci |
NCT05697952: E1K Intra Articular(IA) Treatment for Knee Osteoarthritis |
|
|
| Completed | 2 | 120 | RoW | E1K 1,200 ㎍/joint, E1K 2,400 ㎍/joint, placebo | Ensol Bioscience | Osteoarthrosis | 11/23 | 11/23 | | |
| EP-9001A / Easton Biopharma |
NCT05278611: a Safety and Tolerability Study of EP-9001A in Healthy Volunteers |
|
|
| Recruiting | 1 | 44 | RoW | EP-9001A, NGF mab, placebo | Chengdu Easton Biopharmaceuticals Co,Ltd | Healthy Volunteers | 09/22 | 12/22 | | |
| AK115 / Akesobio |
| No trials found |
